Revvity Inc vs SkyWest Inc — how do they compare? Revvity Inc trades at $155.03 (market cap $16.98B), while SkyWest Inc trades at $95.81 (market cap $3.75B). The key difference: Revvity Inc is far larger — about 4.5× SkyWest Inc's market cap, and Revvity Inc pays a 0.18% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and SkyWest Inc for 8 Days on average.
| RVTY | SKYW | |
|---|---|---|
Market Cap | $16.98B | $3.75B |
Volume | 1,456,900 | 196,324 |
Sector | Health | Industrials |
52-Week High | $157.36 | $115.94 |
52-Week Low | $82.26 | $78.40 |
Typical Hold Time | 12 Days | 8 Days |
Enterprise Value | $19.30B | $5.54B |
Dividend Yield | 0.18% | — |
Signals from Pluang's Aura AI — not financial advice
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
SkyWest (SKYW) trades at $96.64, down 1.1% on the day, with a bearish technical signal from moving averages. The stock shows attractive valuation metrics, including a P/E of 9.6 and P/S of 0.94, while maintaining solid profitability with a 9.78% net income margin. Recent earnings have been mixed, with a Q1 2026 beat but a Q2 2026 miss. Positive developments include fleet modernization efforts and expanded flying agreements, though cost pressures remain a concern.
The investment case balances strong analyst support—58.82% recommend Buy with a $112 consensus target—against near-term technical weakness and earnings volatility. Upside potential exists from operational improvements and cash flow growth, but risks include execution on cost management and broader airline industry challenges. The stock presents a value opportunity for patient investors despite current bearish momentum.
Trailing returns across standard periods
Latest headlines on both assets
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →